Clinical trials: Stage IIC Melanoma
Melanoma
Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells
Background: Sixteen melanoma patients (1 stage IIC, 8 stage III, and 7 stage IV) were treated in a Phase I study to evaluate safety and immune responses, with a vaccine (DC/Apo-Nec) composed of autologous dendritic cells (DCs)…
- Trial name
- NCT00515983
- Testing
- DC/Apo-Nec
- Where
- Argentina
- Volunteers
- 16 people
- Sponsor
- José Mordoh, M.D., Ph.D.
Stage IA Skin Melanoma, Stage IB Skin Melanoma
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma
This pilot clinical trial studies recombinant interferon alfa-2b in treating patients with melanoma. Recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma
- Conditions
- Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma
- Trial name
- NCT01460875
- Testing
- recombinant interferon alfa-2b, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- William Carson
Recurrent Melanoma, Stage IA Skin Melanoma
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
This pilot clinical trial studies booster vaccination in preventing disease recurrence in previously vaccinated patients with melanoma that has been removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma
- Trial name
- NCT01989559
- Testing
- gp100:209-217(210M) Peptide Vaccine, HPV 16 E7:12-20 Peptide Vaccine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Stage IB Skin Melanoma, Stage IIA Skin Melanoma
Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy
This pilot clinical trial studies intravital microscopy in identifying tumor vessels in patients with stage IB-IIIC melanoma undergoing sentinel lymph node biopsy.
- Conditions
- Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma
- Trial name
- NCT02857374
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Giving the vaccine in different ways may make a stronger immune response and kill more tumor cells.
- Trial name
- NCT00398073
- Testing
- mouse gp100 plasmid DNA vaccine, The Dermal PowderMed® devices, intramuscularly (IM injection)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families
This trial studies how well Young Melanoma Family Facebook intervention or Healthy Lifestyle Facebook intervention works in improving skin examination in participants with melanoma and their families.
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8
- Trial name
- NCT03677739
- Testing
- Informational Intervention, Survey Administration
- Where
- 2 sites in United States
- Volunteers
- 1,160 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Melanoma
Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response
The goal of this study is to find out about the safety of injecting the gene (DNA) for mouse TYRP2 in patients with melanoma. DNA is a material that contains the information needed to produce many substances in the body.
- Trial name
- NCT00680589
- Testing
- injection of mouse TYRP2 DNA
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when…
- Trial name
- NCT05608291
- Testing
- Fianlimab, Cemiplimab, Pembrolizumab
- Where
- 211 sites in United States, Argentina and 20 more
- Volunteers
- 1,564 people
- Sponsor
- Regeneron Pharmaceuticals
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Cutaneous Melanoma
Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients
Randomized, open, Phase II-III study, comparative between treatment with CSF-470 vaccine , allogeneic, irradiated with BCG and molgramostin (rHuGM-CSF) as adjuvants and interferon alfa 2b (IFN-alpha2b) treatment , in stages IIB…
- Trial name
- NCT01729663
- Testing
- CSF470 vaccine, BCG, Molgramostim, interferon alpha 2b
- Where
- Argentina
- Volunteers
- 108 people
- Sponsor
- Laboratorio Pablo Cassara S.R.L.
Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
The purpose of the study is to evaluate the pharmacokinetic (PK) equivalence of Bmab1800 as compared with reference product Keytruda® in a randomized, double-blind, two-arm, parallel comparative, multi-center study in patients…
- Trial name
- NCT07581509
- Testing
- Bmab1800, US-Licensed Keytruda
- Where
- Brazil
- Volunteers
- 138 people
- Sponsor
- Biocon Biologics UK PLC